Degree and PhD in Medicine (UB), specialist in Neurosurgery and Global Executive MBA (IESE).

Founding Partner of two Venture Capital funds (Healthequity and Invivo Ventures) focused in early-stage investments in the healthcare sector, where he has led the investment strategy and transaction processes.

He serves or has served at the Board of Directors of many life-sciences companies including Sanifit, Minoryx, Versantis, Glycardial Diagnostics, n-Life Therapeutics, Peptomyc, Arthex, Pulmobiotics, Gyala, Telum, OneChain Immunotherapeutics and Telomere Therapeutics.

Deeply involved in the innovation ecosystem, he is a member and advisor of many healthcare innovation organizations, and author of numerous books in the field of innovation, venture capital and healthcare.

In the academic space, he teaches at several business schools about healthcare innovation and venture capital.

He founded the managing company Invivo Capital Partners together with Albert Ferrer.

Degree in Business Administration and MBA from ESADE, Master CEMS (Community of European Management Schools) in Management from HEC – Hautes Études Commerciales (París) and Chartered Financial Analyst (CFA).

He has been involved in the Spanish VC industry for the past 20 with a focus on high-growth, early stage, technology centered investments.

Member of the board of directors of different portfolio companies: Arthex, Pumobiotics, Gyala, Telum, OneChain Immunotherapeutics and Telomere Therapeutics.

He is as well currently Director of Healthequity, a venture capital fund focused in early-stage companies in the healthcare sector, where he led the investment strategy and transaction processes of the different portfolio companies. He has been a member of the Board of Directors of different life-sciences companies and of Healthequity's investments: Sanifit, Peptomyc and Glycardial Diagnostics.

Previously, he led Spinnaker Invest, VC firm within Grupo Financiero Riva y García. He has been as well a member of the Board of Directors of various companies such as Exoticca, Wecare-u and Scytl.

He founded the managing company Invivo Capital Partners together with Luis Pareras.

Bachelor of Science in Biotechnology (UAB), PhD in Biotechnology (UB) and a Postgraduate course in Innovation Management (UAB).

Her research in gene therapy applications in the cancer field have led to publications in scientific journals and collaborations with biotech companies. 

She has been Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona.

She collaborates with different entities of the health innovation ecosystem as a start-up mentor, jury and evaluator (COMB, EIT Health, Ship2b, Imagine IF!, FIPSE and CIMTI, among others).

Since January 2018, she works as Investment Analyst in Healthequity, and since 2019 at Invivo Ventures, the first fund of Invivo Capital Partners.

She is Observer at the Board of Arthex, Pulmobiotics, Gyala, Telum, OneChain Immunotherapeutics and Telomere Therapeutics.

Currently she is Principal at Invivo Capital Partners.

BSc & MSc Civil and transport Engineering (UPC) and BSc Economics (UB).

He has worked in the financial and operations department of the technologic start-up Exoticca, collaborating in the fundraising of the company, and in n a financial boutique specialized in M&A from the Spanish industrial sector.

Moreover, he has consulting experience in the financial, engineering and market intelligence consulting sectors.

Since April 2019, he works as an Investment Analyst in Healthequity and Invivo Ventures, Invivo Capital Partners first fund.

Bachelor of Science in Biomedical Sciences (UB), Master of Science in Business Management applied to the Biotechnology Sector and Pharmaceutical Industry, specialized in Project Management (BBI) and Postgraduate course in Financing (UPF Barcelona School of Management).

She has been Project Manager in UPF Ventures, an innovation management firm owned by Universitat Pompeu Fabra (UPF).

She is member of the EIT Health Alumni Network, after her participation in the StarShip Program (2019) organized by EIT Health in collaboration with leading European universities (University of Oxford, IESE Business School) and industrial partners (GE Healthcare).

She usually collaborates with different entities of the health innovation ecosystem as an innovation projects and start-up evaluator (COMB, EIT Health, CIMTI, The Collider, among others),

Since May 2020, she works as an Investment Analyst at Invivo Ventures, the first fund of Invivo Capital Partners.

Bachelor of Science in Biotechnology (UVic), Master of Science in Business Administration and Bioentrepreneurship (Copenhagen Business School and Copenhagen University), Master of Science in Health Economics and Pharmacoeconomics (UPF Barcelona School of Management) and CEIPI basic training course in European patent law (Université de Strasbourg).

She has been Project Manager in the Knowledge Transfer and Innovation Unit at the Universitat Autònoma de Barcelona (UAB).

She collaborates with different entities of the health innovation ecosystem as an innovation projects and start-up evaluator (COMB, IRS, Ideas Generation Program (PRUAB), among others).

Since September 2021, she works as an Investment Analyst at Invivo Ventures, the first fund of Invivo Capital Partners.

She has worked as Office Manager and Executive Assistant for 18 years carrying out administration tasks, client and supplier relations, agenda, conference and travel planning and management, both for the directors and the team, at the Barcelona Medical Association and Healthequity since it was founded in 2012.

Between 2009 and 2019, she managed 25 editions of the Healthcare Investment Forums and the Ready4Growth seminar.

Since June 2019, she works as an Executive Assistant, Office Manager and Social Media Manager at Invivo Ventures, the first fund of Invivo Capital Partners.